TY  - JOUR
AU  - Joensuu, Heikki
AU  - Blay, Jean-Yves
AU  - Comandone, Alessandro
AU  - Martin-Broto, Javier
AU  - Fumagalli, Elena
AU  - Grignani, Giovanni
AU  - Del Muro, Xavier Garcia
AU  - Adenis, Antoine
AU  - Valverde, Claudia
AU  - Pousa, Antonio Lopez
AU  - Bouché, Olivier
AU  - Italiano, Antoine
AU  - Bauer, Sebastian
AU  - Barone, Carlo
AU  - Weiss, Claudia
AU  - Crippa, Stefania
AU  - Camozzi, Maura
AU  - Castellana, Ramon
AU  - Le Cesne, Axel
PY  - 2017
DO  - 10.1038/bjc.2017.290
UR  - http://hdl.handle.net/10668/11536
T2  - British journal of cancer
AB  - This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of dovitinib as second-line treatment of patients with gastrointestinal stromal tumour (GIST) refractory to imatinib or who do not tolerate imatinib. Patients received oral...
LA  - en
KW  - Adult
KW  - Aged
KW  - Benzimidazoles
KW  - Biomarkers, Tumor
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Follow-Up Studies
KW  - Gastrointestinal Neoplasms
KW  - Gastrointestinal Stromal Tumors
KW  - Humans
KW  - Imatinib Mesylate
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Prognosis
KW  - Protein Kinase Inhibitors
KW  - Quinolones
KW  - Salvage Therapy
TI  - Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.
TY  - research article
VL  - 117
ER  -